Stallergenes and DBV Technologies Enter Into Partnership for the Development of Innovative Treatment of Respiratory Allergies Partnership to Develop Immunotherapy Treatments for Respiratory Allergies Using DBV’s Skin Patch, Viaskin(R)
ANTONY and BAGNEUX, France I May 16, 2013 I DBV Technologies (EURONEXT PARIS: DBV) (ISIN:FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and Stallergenes S.A. (Euronext Paris CAC small), worldwide leader in allergen immunotherapy, announced today that they have entered into a strategic research partnership.
This partnership combines Stallergenes’ world class know-how in respiratory allergies with DBV’s Viaskin, a unique platform allowing for epicutaneous desensitization. DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin® and Stallergenes’ aeroallergens. Stallergenes will finance all of DBV’s research on these aeroallergens and will have development and commercialization rights. In the coming months, the parties will enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization.
Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: “The agreement with Stallergenes is very much in line with our strategy to expand our Viaskin® proprietary platform beyond food allergies. Stallergenes is an ideal partner and has the expertise in respiratory allergies, a major health issue affecting approximately 20% of the general population. Both companies share a passion for innovation, and I strongly believe that the combination of our respective strengths will lead to best-in-class treatments for the benefit of patients.”
Dr. Roberto Gradnik, CEO of Stallergenes, said: “We are very pleased to team up with DBV Technologies, a company that is developing innovative products designed to deliver allergens with epicutaneous immunotherapy. This collaboration will reinforce our deep expertise in allergen immunotherapy, well-established for more than 50 years, and demonstrates our continuous focus on innovation. Our expertise combined with DBV’s new route of administration will give the opportunity to patients, especially young children, to benefit from a new innovative solution in allergen immunotherapy.”
About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of allergy — a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy — a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
SOURCE: DBV Technologies
Post Views: 268
Stallergenes and DBV Technologies Enter Into Partnership for the Development of Innovative Treatment of Respiratory Allergies Partnership to Develop Immunotherapy Treatments for Respiratory Allergies Using DBV’s Skin Patch, Viaskin(R)
ANTONY and BAGNEUX, France I May 16, 2013 I DBV Technologies (EURONEXT PARIS: DBV) (ISIN:FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and Stallergenes S.A. (Euronext Paris CAC small), worldwide leader in allergen immunotherapy, announced today that they have entered into a strategic research partnership.
This partnership combines Stallergenes’ world class know-how in respiratory allergies with DBV’s Viaskin, a unique platform allowing for epicutaneous desensitization. DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin® and Stallergenes’ aeroallergens. Stallergenes will finance all of DBV’s research on these aeroallergens and will have development and commercialization rights. In the coming months, the parties will enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization.
Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: “The agreement with Stallergenes is very much in line with our strategy to expand our Viaskin® proprietary platform beyond food allergies. Stallergenes is an ideal partner and has the expertise in respiratory allergies, a major health issue affecting approximately 20% of the general population. Both companies share a passion for innovation, and I strongly believe that the combination of our respective strengths will lead to best-in-class treatments for the benefit of patients.”
Dr. Roberto Gradnik, CEO of Stallergenes, said: “We are very pleased to team up with DBV Technologies, a company that is developing innovative products designed to deliver allergens with epicutaneous immunotherapy. This collaboration will reinforce our deep expertise in allergen immunotherapy, well-established for more than 50 years, and demonstrates our continuous focus on innovation. Our expertise combined with DBV’s new route of administration will give the opportunity to patients, especially young children, to benefit from a new innovative solution in allergen immunotherapy.”
About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of allergy — a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy — a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
SOURCE: DBV Technologies
Post Views: 268
